Idiopathic pulmonary fibrosis (IPF) involves
collagen deposition that results in a progressive decline in lung function. This process involves activation of Smad2/3 by
transforming growth factor (TGF)-β and Wnt signaling pathways.
Collagen Triple Helix Repeat-Containing-1 (Cthrc1)
protein inhibits Smad2/3 activation. To test the hypothesis that Cthrc1 limits
collagen deposition and the decline of lung function, Cthrc1 knockout (Cthrc1-/-) and wild-type mice (WT) received intratracheal
injections of 2.5 U/kg
bleomycin or saline. Lungs were harvested after 14 days and Bronchoalveolar lavage (BAL) TGF-β, IL1-β,
hydroxyproline and lung compliance were assessed. TGF-β was significantly higher in Cthrc1-/- compared to WT (53.45 ± 6.15 ng/mL vs. 34.48 ± 11.05) after saline injection.
Bleomycin injection increased TGF-β in both Cthrc1-/- (66.37 ± 8.54 ng/mL) and WT (63.64 ± 8.09 ng/mL).
Hydroxyproline was significantly higher in Cthrc1-/- compared to WT after
bleomycin-injection (2.676 ± 0.527 μg/mg vs. 1.889 ± 0.520, P = 0.028). Immunohistochemistry of Cthrc1-/- lung sections showed intracellular localization and activation of β-
catenin Y654 in areas of tissue remodeling that was not evident in WT Lung compliance was significantly reduced by
bleomycin in Cthrc1-/- but there was no effect in WT animals. These data suggest Cthrc1 reduces fibrotic tissue formation
in bleomycin-induced lung
fibrosis and the effect is potent enough to limit the decline in lung function. We conclude that Cthrc1 plays a protective role, limiting
collagen deposition and could form the basis of a novel
therapy for
pulmonary fibrosis.